SYNEOS HEALTH INC (SYNH) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SYNH • US87166B1026

42.98 USD
+0.01 (+0.02%)
At close: Sep 27, 2023
42.97 USD
-0.01 (-0.02%)
After Hours: 9/27/2023, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, SYNH scores 4 out of 10 in our fundamental rating. SYNH was compared to 58 industry peers in the Life Sciences Tools & Services industry. There are concerns on the financial health of SYNH while its profitability can be described as average. SYNH may be a bit undervalued, certainly considering the very reasonable score on growth


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • SYNH had positive earnings in the past year.
  • In the past year SYNH had a positive cash flow from operations.
SYNH Yearly Net Income VS EBIT VS OCF VS FCFSYNH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M 300M 400M

1.2 Ratios

  • SYNH has a Return On Assets of 0.88%. This is in the better half of the industry: SYNH outperforms 70.31% of its industry peers.
  • SYNH has a better Return On Equity (2.04%) than 71.88% of its industry peers.
  • SYNH's Return On Invested Capital of 4.23% is fine compared to the rest of the industry. SYNH outperforms 70.31% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for SYNH is significantly below the industry average of 13.29%.
Industry RankSector Rank
ROA 0.88%
ROE 2.04%
ROIC 4.23%
ROA(3y)2.83%
ROA(5y)2.12%
ROE(3y)6.82%
ROE(5y)5.13%
ROIC(3y)4.99%
ROIC(5y)4.67%
SYNH Yearly ROA, ROE, ROICSYNH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 10 20 30

1.3 Margins

  • SYNH's Profit Margin of 1.31% is fine compared to the rest of the industry. SYNH outperforms 70.31% of its industry peers.
  • In the last couple of years the Profit Margin of SYNH has grown nicely.
  • SYNH has a Operating Margin of 6.33%. This is in the better half of the industry: SYNH outperforms 65.63% of its industry peers.
  • SYNH's Operating Margin has improved in the last couple of years.
  • With a Gross Margin value of 22.14%, SYNH is not doing good in the industry: 84.38% of the companies in the same industry are doing better.
  • SYNH's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 6.33%
PM (TTM) 1.31%
GM 22.14%
OM growth 3Y5.34%
OM growth 5Y13.1%
PM growth 3Y20.73%
PM growth 5YN/A
GM growth 3Y1.57%
GM growth 5Y0.02%
SYNH Yearly Profit, Operating, Gross MarginsSYNH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 10 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SYNH is destroying value.
  • The number of shares outstanding for SYNH has been reduced compared to 1 year ago.
  • The debt/assets ratio for SYNH has been reduced compared to a year ago.
SYNH Yearly Shares OutstandingSYNH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
SYNH Yearly Total Debt VS Total AssetsSYNH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2B 4B 6B 8B

2.2 Solvency

  • SYNH has an Altman-Z score of 1.46. This is a bad value and indicates that SYNH is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.46, SYNH is in line with its industry, outperforming 43.75% of the companies in the same industry.
  • The Debt to FCF ratio of SYNH is 16.71, which is on the high side as it means it would take SYNH, 16.71 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 16.71, SYNH is in the better half of the industry, outperforming 65.63% of the companies in the same industry.
  • A Debt/Equity ratio of 0.77 indicates that SYNH is somewhat dependend on debt financing.
  • The Debt to Equity ratio of SYNH (0.77) is worse than 79.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 16.71
Altman-Z 1.46
ROIC/WACC0.39
WACC10.92%
SYNH Yearly LT Debt VS Equity VS FCFSYNH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B

2.3 Liquidity

  • SYNH has a Current Ratio of 1.20. This is a normal value and indicates that SYNH is financially healthy and should not expect problems in meeting its short term obligations.
  • SYNH's Current ratio of 1.20 is on the low side compared to the rest of the industry. SYNH is outperformed by 93.75% of its industry peers.
  • SYNH has a Quick Ratio of 1.20. This is a normal value and indicates that SYNH is financially healthy and should not expect problems in meeting its short term obligations.
  • SYNH has a Quick ratio of 1.20. This is amonst the worse of the industry: SYNH underperforms 82.81% of its industry peers.
Industry RankSector Rank
Current Ratio 1.2
Quick Ratio 1.2
SYNH Yearly Current Assets VS Current LiabilitesSYNH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for SYNH have decreased strongly by -23.79% in the last year.
  • The Earnings Per Share has been growing by 13.74% on average over the past years. This is quite good.
  • Looking at the last year, SYNH shows a small growth in Revenue. The Revenue has grown by 0.01% in the last year.
  • The Revenue has been growing by 15.08% on average over the past years. This is quite good.
EPS 1Y (TTM)-23.79%
EPS 3Y13.48%
EPS 5Y13.74%
EPS Q2Q%-54.4%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y4.87%
Revenue growth 5Y15.08%
Sales Q2Q%0.39%

3.2 Future

  • Based on estimates for the next years, SYNH will show a small growth in Earnings Per Share. The EPS will grow by 3.17% on average per year.
  • Based on estimates for the next years, SYNH will show a small growth in Revenue. The Revenue will grow by 1.71% on average per year.
EPS Next Y-25.43%
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%
EPS Next 5Y3.17%
Revenue Next Year-2.82%
Revenue Next 2Y-0.54%
Revenue Next 3Y1.03%
Revenue Next 5Y1.71%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SYNH Yearly Revenue VS EstimatesSYNH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B 4B 5B
SYNH Yearly EPS VS EstimatesSYNH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 11.37, which indicates a very decent valuation of SYNH.
  • 100.00% of the companies in the same industry are more expensive than SYNH, based on the Price/Earnings ratio.
  • SYNH's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.06.
  • The Price/Forward Earnings ratio is 10.48, which indicates a very decent valuation of SYNH.
  • Based on the Price/Forward Earnings ratio, SYNH is valued cheaper than 100.00% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of SYNH to the average of the S&P500 Index (27.86), we can say SYNH is valued rather cheaply.
Industry RankSector Rank
PE 11.37
Fwd PE 10.48
SYNH Price Earnings VS Forward Price EarningsSYNH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 95.31% of the companies in the same industry are more expensive than SYNH, based on the Enterprise Value to EBITDA ratio.
  • SYNH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SYNH is cheaper than 85.94% of the companies in the same industry.
Industry RankSector Rank
P/FCF 27.53
EV/EBITDA 12.05
SYNH Per share dataSYNH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)0.83
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for SYNH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SYNEOS HEALTH INC

NASDAQ:SYNH (9/27/2023, 8:00:01 PM)

After market: 42.97 -0.01 (-0.02%)

42.98

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-09
Earnings (Next)11-02
Inst Owners0%
Inst Owner Change0%
Ins Owners0.49%
Ins Owner Change0%
Market Cap4.46B
Revenue(TTM)5.42B
Net Income(TTM)71.22M
Analysts53.75
Price Target43.35 (0.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.02%
Min EPS beat(2)-29.57%
Max EPS beat(2)11.52%
EPS beat(4)2
Avg EPS beat(4)-6.43%
Min EPS beat(4)-29.57%
Max EPS beat(4)11.52%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.57%
Min Revenue beat(2)3.81%
Max Revenue beat(2)5.33%
Revenue beat(4)3
Avg Revenue beat(4)1.96%
Min Revenue beat(4)-4.69%
Max Revenue beat(4)5.33%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.13%
EPS NQ rev (1m)-1.52%
EPS NQ rev (3m)0.41%
EPS NY rev (1m)1.03%
EPS NY rev (3m)4.38%
Revenue NQ rev (1m)0.31%
Revenue NQ rev (3m)1.89%
Revenue NY rev (1m)0.55%
Revenue NY rev (3m)2.45%
Valuation
Industry RankSector Rank
PE 11.37
Fwd PE 10.48
P/S 0.82
P/FCF 27.53
P/OCF 17.62
P/B 1.28
P/tB N/A
EV/EBITDA 12.05
EPS(TTM)3.78
EY8.79%
EPS(NY)4.1
Fwd EY9.54%
FCF(TTM)1.56
FCFY3.63%
OCF(TTM)2.44
OCFY5.67%
SpS52.25
BVpS33.68
TBVpS-19.54
PEG (NY)N/A
PEG (5Y)0.83
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.88%
ROE 2.04%
ROCE 5.32%
ROIC 4.23%
ROICexc 4.29%
ROICexgc 32.26%
OM 6.33%
PM (TTM) 1.31%
GM 22.14%
FCFM 2.99%
ROA(3y)2.83%
ROA(5y)2.12%
ROE(3y)6.82%
ROE(5y)5.13%
ROIC(3y)4.99%
ROIC(5y)4.67%
ROICexc(3y)5.11%
ROICexc(5y)4.79%
ROICexgc(3y)50.55%
ROICexgc(5y)76.43%
ROCE(3y)6.27%
ROCE(5y)5.87%
ROICexgc growth 3Y-8.19%
ROICexgc growth 5Y1.51%
ROICexc growth 3Y6.95%
ROICexc growth 5Y27.79%
OM growth 3Y5.34%
OM growth 5Y13.1%
PM growth 3Y20.73%
PM growth 5YN/A
GM growth 3Y1.57%
GM growth 5Y0.02%
F-Score6
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 16.71
Debt/EBITDA 4.56
Cap/Depr 37.2%
Cap/Sales 1.68%
Interest Coverage 250
Cash Conversion 43.05%
Profit Quality 227.34%
Current Ratio 1.2
Quick Ratio 1.2
Altman-Z 1.46
F-Score6
WACC10.92%
ROIC/WACC0.39
Cap/Depr(3y)28.14%
Cap/Depr(5y)26.15%
Cap/Sales(3y)1.32%
Cap/Sales(5y)1.31%
Profit Quality(3y)162.48%
Profit Quality(5y)341.03%
High Growth Momentum
Growth
EPS 1Y (TTM)-23.79%
EPS 3Y13.48%
EPS 5Y13.74%
EPS Q2Q%-54.4%
EPS Next Y-25.43%
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%
EPS Next 5Y3.17%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y4.87%
Revenue growth 5Y15.08%
Sales Q2Q%0.39%
Revenue Next Year-2.82%
Revenue Next 2Y-0.54%
Revenue Next 3Y1.03%
Revenue Next 5Y1.71%
EBIT growth 1Y-27.25%
EBIT growth 3Y10.47%
EBIT growth 5Y30.16%
EBIT Next Year-2.87%
EBIT Next 3Y4.37%
EBIT Next 5Y3.5%
FCF growth 1Y-63.52%
FCF growth 3Y9.43%
FCF growth 5Y16.65%
OCF growth 1Y-47.97%
OCF growth 3Y10.26%
OCF growth 5Y16.58%

SYNEOS HEALTH INC / SYNH FAQ

What is the ChartMill fundamental rating of SYNEOS HEALTH INC (SYNH) stock?

ChartMill assigns a fundamental rating of 5 / 10 to SYNH.


What is the valuation status of SYNEOS HEALTH INC (SYNH) stock?

ChartMill assigns a valuation rating of 7 / 10 to SYNEOS HEALTH INC (SYNH). This can be considered as Undervalued.


Can you provide the profitability details for SYNEOS HEALTH INC?

SYNEOS HEALTH INC (SYNH) has a profitability rating of 6 / 10.


What is the financial health of SYNEOS HEALTH INC (SYNH) stock?

The financial health rating of SYNEOS HEALTH INC (SYNH) is 4 / 10.


Can you provide the expected EPS growth for SYNH stock?

The Earnings per Share (EPS) of SYNEOS HEALTH INC (SYNH) is expected to decline by -25.43% in the next year.